Monte Rosa Therapeutics Inc (GLUE NASDAQ) stock market data APIs
$10.1376
0.08(0.8%)
as of October 17, 2025
Try our APIs with
free plan!
Monte Rosa Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Prev. Close
10.1376
Open
10.2226
High
10.3489
Low
9.6469
52 wk Range
3.5001-12.4
Market Cap
621 M
P/E Ratio
25.7692
Shares Outstanding
61 759 K
Revenue
178 M
EPS
-0.356
Beta
1.539
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Monte Rosa Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Monte Rosa Therapeutics Inc data using free add-ons & libraries
Get Monte Rosa Therapeutics Inc Fundamental Data
Monte Rosa Therapeutics Inc Fundamental data includes:
- Net Revenue: 178 M
- EBITDA: 23 296 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Monte Rosa Therapeutics Inc News
New
Should You Buy Novartis Stock Before October 28?
Switzerland-based global healthcare company Novartis (NVS) is gaining momentum this year, thanks to solid pipeline execution, new regulatory wins, high-value license transactions, capital return to sh...
Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is among the best fast money stocks to buy now. During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. ...
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Shares of clinical-stage biotech Monte Rosa Therapeutics GLUE rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis NVS to develop novel molecula...
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics GLUE shares soared 44.1% in the last trading session to close at $6.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This c...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
